NCT05480956 (SHAPE) is a NA clinical trial of SIRI Checklist in HIV Infections, sponsored by University of Alabama at Birmingham.

Who is sponsoring NCT05480956?

NCT05480956 is sponsored by University of Alabama at Birmingham.

What drugs are being tested in NCT05480956?

Interventions in NCT05480956: SIRI Checklist, Enhanced Peer Recovery Coach, SIRI Checklist + Enhanced Peer Recovery Coach.

What condition does NCT05480956 study?

NCT05480956 studies HIV Infections, Opioid-Related Disorders, Pre-Exposure Prophylaxis (PrEP).

Is NCT05480956 still recruiting?

NCT05480956 is currently completed. Last updated 18 February 2026.

Last reviewed 2026-02-18 · How we verify

NCT05480956: SHAPE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SIRI Checklist: An Integrated Hospital Model to Optimize HIV Prevention in Persons Who Inject Drugs

Completed NA Last updated 18 February 2026

What this trial tests

NA trial testing SIRI Checklist in HIV Infections in 60 participants. Completed in 1 July 2025.

Timeline

11 October 2022

Primary endpoint
1 July 2025

1 July 2025

Quick facts

Lead sponsor	University of Alabama at Birmingham
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	factorial
Masking	none
Primary purpose	prevention
Enrollment	60
Start date	11 October 2022
Primary completion	1 July 2025
Estimated completion	1 July 2025
Sites	1 location across United States

Drugs / interventions tested

SIRI Checklist
Enhanced Peer Recovery Coach
SIRI Checklist + Enhanced Peer Recovery Coach

Conditions studied

HIV Infections — all drugs for HIV Infections →
Opioid-Related Disorders — all drugs for Opioid-Related Disorders →
Pre-Exposure Prophylaxis (PrEP) — all drugs for Pre-Exposure Prophylaxis (PrEP) →

Sponsor

University of Alabama at Birmingham

Who can join

18 and older, any sex, with HIV Infections or Opioid-Related Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to develop and test a serious injection-related injections (SIRI) checklist aimed at increasing evidence-based treatment for rural people who use drugs (PWUD) including innovative, long-acting injectable agents. The central hypothesis is that hospital-based care models can successfully engage rural and Southern (PWUD) in effective addiction treatment and infection prevention. The activities in this study will be foundational to Ending the HIV epidemic in rural states.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A Study Protocol to Increase Engagement in Evidence Based Hospital and Community Based Care Using a Serious Injection Related Infections (SIRI) Checklist and Enhanced Peer for Hospitalized PWID (ShaPe)
Baldwin M, Jeziorski M, Parman M, Gagnon K, et al · · 2023 · DOI 10.21203/rs.3.rs-2546488/v1

Verify or expand the search:

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting

Other University of Alabama at Birmingham trials

Trials by the same sponsor.

NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05480956 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
Last refreshed: 18 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05480956.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing